Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) released its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.02, Briefing.com reports. Progenics Pharmaceuticals had a negative return on equity of 67.61% and a negative net margin of 445.81%. The business had revenue of $2.70 million during the quarter, compared to analysts’ expectations of $3.58 million. During the same quarter last year, the business posted $0.52 EPS. The business’s revenue was down 95.0% on a year-over-year basis.
Shares of Progenics Pharmaceuticals (NASDAQ PGNX) traded down $0.09 during mid-day trading on Monday, hitting $5.60. The stock had a trading volume of 631,400 shares, compared to its average volume of 1,110,001. Progenics Pharmaceuticals has a 1 year low of $4.60 and a 1 year high of $11.72. The company has a current ratio of 7.86, a quick ratio of 7.86 and a debt-to-equity ratio of 0.80.
A number of research firms recently weighed in on PGNX. ValuEngine lowered Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, October 6th. Cantor Fitzgerald reissued a “buy” rating and issued a $15.00 target price on shares of Progenics Pharmaceuticals in a report on Wednesday, September 27th. Needham & Company LLC reissued a “strong-buy” rating and issued a $14.00 target price on shares of Progenics Pharmaceuticals in a report on Friday, September 1st. Zacks Investment Research lowered Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, October 18th. Finally, Aegis reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Progenics Pharmaceuticals in a report on Tuesday, August 22nd. Three equities research analysts have rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Hold” and an average target price of $13.20.
ILLEGAL ACTIVITY WARNING: “Progenics Pharmaceuticals Inc. (PGNX) Releases Earnings Results, Beats Estimates By $0.02 EPS” was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://ledgergazette.com/2017/11/13/progenics-pharmaceuticals-inc-pgnx-posts-earnings-results-beats-estimates-by-0-02-eps.html.
About Progenics Pharmaceuticals
Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.
Receive News & Ratings for Progenics Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.